Patents by Inventor Neil I. Goldstein

Neil I. Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin and IGF-1 Receptor Agonists and Antagonists
    Publication number: 20110124556
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: April 20, 2010
    Publication date: May 26, 2011
    Applicants: NOVO NORDISK A/S, ANTYRA INC.
    Inventors: RENUKA PILLUTLA, RENEE BRISSETTE, ARTHUR J. BLUME, LAUGE SCHAFFER, JAKOB BRANDT, NEIL I. GOLDSTEIN, JANE SPETZLER, SOREN OSTERGAARD, PER HERTZ HANSEN
  • Insulin and IGF-1 Receptor Agonists and Antagonists
    Publication number: 20090192072
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: November 21, 2008
    Publication date: July 30, 2009
    Applicants: Novo Nordisk A/S, Antyra Inc. (formerly DGI Bio Technologies)
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • ANTIBODY AND ANTIBODY FRAGMENTS FOR INHIBITING THE GROWTH OF TUMORS
    Publication number: 20090099339
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: July 9, 2008
    Publication date: April 16, 2009
    Applicant: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Insulin and IGF-1 Receptor Agonists and Antagonists
    Publication number: 20090053807
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
    Type: Application
    Filed: December 3, 2007
    Publication date: February 26, 2009
    Applicants: Novo Nordisk A/S, Antyra Inc.
    Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-chuan Hsiao, Michael Lennick, Paul Fletcher
  • Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
    Publication number: 20090022714
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGFR antagonist and an EGFR antagonist.
    Type: Application
    Filed: October 20, 2006
    Publication date: January 22, 2009
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • COMBINATION METHODS OF INHIBITING TUMOR GROWTH WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST
    Publication number: 20090022716
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 22, 2009
    Applicant: IMCLONE SYSTEMS INC.
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Insulin and IGF-1 receptor agonists and antagonists
    Patent number: 7173005
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: February 6, 2007
    Assignees: Antyra Inc., Novo Nordisk A/S
    Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
  • Humanized anti-EGF receptor monoclonal antibody
    Patent number: 7060808
    Abstract: A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: June 13, 2006
    Assignee: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Insulin and IGF-1 receptor agonists and antagonists
    Patent number: 6875741
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: April 5, 2005
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
  • Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
    Patent number: 6811779
    Abstract: The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: November 2, 2004
    Assignee: ImClone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Insulin and IGF-1 receptor agonists and antagonists
    Publication number: 20040023887
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2002
    Publication date: February 5, 2004
    Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
  • Antibody and antibody fragments for inhibiting the growth of tumors
    Publication number: 20040006212
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: January 8, 2004
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Isulin and IGF-1 receptor agonists and antagonists
    Publication number: 20030236190
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2002
    Publication date: December 25, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Antibody and antibody fragments for inhibiting the growth of tumors
    Publication number: 20030224001
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: December 4, 2003
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Methods for identifying oncogenes and tumor-associated proteins
    Publication number: 20030219821
    Abstract: This invention provides a method for preparing antibodies directed against a protein associated with a cancer, comprising the steps of:
    Type: Application
    Filed: May 6, 2002
    Publication date: November 27, 2003
    Inventors: Paul B. Fisher, Neil I. Goldstein
  • Insulin and IGF-1 receptor agonists and antagonists
    Publication number: 20030195147
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2001
    Publication date: October 16, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
    Publication number: 20030108545
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 12, 2003
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
    Publication number: 20030103973
    Abstract: The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.
    Type: Application
    Filed: March 2, 2001
    Publication date: June 5, 2003
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Publication number: 20020192213
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 19, 2002
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Chimeric and humanized monoclonal antibodies specific to VEGF receptors
    Patent number: 6448077
    Abstract: Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: September 10, 2002
    Assignee: ImClone Systems, Inc.
    Inventors: Patricia Rockwell, Neil I. Goldstein